Research programme: logic gated chimeric antigen receptor T-cell therapies - ArsenalBio
Alternative Names: Chimaeric antigen receptor T-cell therapies - ArsenalBio; Logic gated chimeric antigen receptor T-cell therapies - ArsenalBio; Research programme: logic gated chimaeric antigen receptor T cell therapies - ArsenalBioLatest Information Update: 26 Jul 2023
At a glance
- Originator ArsenalBio
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 14 Apr 2023 Preclinical trials in Solid tumours in USA (Parenteral)
- 14 Apr 2023 Pharmacodynamics data from a preclinical studies in Solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 10 Jan 2022 ArsenalBio and Bristol Myers Squibb expandes a licensing agreement for the candidates developed from this research programme